{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lacerations/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field 360a5a37-7d25-4abe-9c79-a79a00c732e0 --><h2>Flucloxacillin</h2><!-- end field 360a5a37-7d25-4abe-9c79-a79a00c732e0 -->","summary":"","htmlStringContent":"<!-- begin item d670e905-3c76-4124-acb3-a79a00c72ef1 --><!-- end item d670e905-3c76-4124-acb3-a79a00c72ef1 -->","topic":{"id":"bc1075da-03fb-510a-aafc-42f8402c77bb","topicId":"c455b3ad-86f5-4c2b-a00d-ceb66ba46f46","topicName":"Lacerations","slug":"lacerations","lastRevised":"Last revised in January 2021","chapters":[{"id":"abcb9c5e-8c70-578e-b2f1-2bfe9e0e6dea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b3295eac-08d7-597e-9bbf-240c812490a5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes"},{"id":"d164a0e0-2763-5ec6-8aaa-1f68fe1d381c","slug":"update","fullItemName":"Update"}]},{"id":"e6d917bb-ce9e-58a6-8b13-cf3e389a6aef","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"83820372-5bd1-5e60-a139-cd76615ac683","slug":"goals","fullItemName":"Goals"},{"id":"15606cb7-089f-5a7d-af3f-d4b9c9b0d2be","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1a9aa28b-0708-5c58-843c-05a09196b471","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"682e483f-7847-5e82-be10-969f896d9533","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0db2153f-bcb4-5382-9178-92d651a01c4e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3929f359-184e-53d4-8aca-a4081b967c1a","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"313e7f7d-a625-5b48-a31d-e5f00ca31462","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0ad26899-0f07-5523-8ea6-17d520df4cc8","slug":"definition","fullItemName":"Definition"},{"id":"e917af1e-ca7f-5ddd-9cb9-1132ce21b4a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe57a056-8e82-56fa-bb79-87f037fb4303","slug":"complications","fullItemName":"Complications"}]},{"id":"e01eac70-aab4-50c3-a90e-7b07194bf1c8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c1be68cd-346e-504f-b22f-e8352fc5c3f6","slug":"assessment","fullItemName":"Assessment"}]},{"id":"35a250d2-9a3b-5287-8afa-d73dfc12c39b","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c6adc10-cc7f-5820-b2da-874e89c9b72b","slug":"laceration-low-infection-risk","fullItemName":"Scenario: Laceration - low infection risk"},{"id":"496fa19f-131c-5dd3-8be3-ae041478b608","slug":"laceration-high-infection-risk","fullItemName":"Scenario: Laceration - high infection risk"},{"id":"9204ec1a-d022-5955-9f74-6b4eb51bf9a9","slug":"laceration-infected","fullItemName":"Scenario: Laceration - infected"}]},{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8f912e41-1ff8-5fce-b9b4-6b3524e8f79b","slug":"tetanus-booster","fullItemName":"Tetanus booster"}]},{"id":"b1fc897d-bfab-5305-bcf1-70e0f4598e5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"18a38028-bff4-54de-948c-9715f3649589","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0132c748-edac-513b-a351-59a838b07e61","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b4b28cd4-4652-528e-aa28-23f341c6a31e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b86d931b-dadb-55a7-92c8-6cdb81ce5d7f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6695afc-2f21-5bf7-907b-68a0fb3a77c4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d4ab79d3-d601-5b9b-b2b5-d3256e138671","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc9ca4ec-c56f-5acc-830c-ccf5c31d5f67","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"da87988b-1b2a-5d33-a4d0-ab4caed97670","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 96741eb7-f998-4682-937e-a79a00c7bf40 --><h3>What are the licensed doses?</h3><!-- end field 96741eb7-f998-4682-937e-a79a00c7bf40 -->","summary":"","htmlStringContent":"<!-- begin item 3f81bca5-667c-4d7b-bad8-a79a00c7bd0b --><!-- begin field 1319726d-3981-41b7-9539-a79a00c7bf40 --><ul><li><strong>Prescribe flucloxacillin for 5–7 days. The licensed oral doses are:</strong><ul><li><strong>Children aged 1 month to 1 year </strong>— 62.5–125 mg 4 times a day.</li><li><strong>Children aged 2 years to 9 years </strong>—125–250 mg 4 times a day.</li><li><strong>Adults and children aged 10 years and over </strong>— 250–500 mg 4 times a day.</li></ul></li><li><strong>In renal impairment:</strong><ul><li><strong>In adults, </strong>reduce the dose if estimated glomerular filtration rate (eGFR) is less than 10 mL/minute/1.73 m<sup>2</sup>.</li><li><strong>In children, </strong>use the normal dose every 8 hours if eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF for Children, 2017</a>]</p><!-- end field 1319726d-3981-41b7-9539-a79a00c7bf40 --><!-- end item 3f81bca5-667c-4d7b-bad8-a79a00c7bd0b -->","subChapters":[]},{"id":"be34a3cf-a7d7-5fc4-9490-9c6f32b26cf8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 42fe8b36-66b5-47c4-9bec-a79a00c7d322 --><h3>What are the contraindications and cautions for flucloxacillin?</h3><!-- end field 42fe8b36-66b5-47c4-9bec-a79a00c7d322 -->","summary":"","htmlStringContent":"<!-- begin item b5b29ad5-86c5-4bad-91a2-a79a00c7d160 --><!-- begin field 16921f2f-3a82-4466-8066-a79a00c7d322 --><ul><li><strong>Do not prescribe flucloxacillin</strong> <strong>to people with:</strong><ul><li>A true penicillin allergy — gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin.</li><li>History of flucloxacillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe flucloxacillin with caution</strong> <strong>to people with: </strong><ul><li>Hepatic dysfunction (not flucloxacillin-related), especially if they are 50 years of age or older, or have a serious underlying medical condition.</li><li>End stage renal impairment — reduce the <a class=\"topic-reference internal-reference\" href=\"/topics/lacerations/prescribing-information/flucloxacillin/#licensed-doses\">dose</a> if the person's estimated glomerular filtration rate (eGFR) is less than 10 mL/minute/1.73 m<sup>2</sup>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]</p><!-- end field 16921f2f-3a82-4466-8066-a79a00c7d322 --><!-- end item b5b29ad5-86c5-4bad-91a2-a79a00c7d160 -->","subChapters":[]},{"id":"2df3b7cf-f465-5cd8-88f5-23c0172fc392","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a8c04b3c-a46e-4e8b-9707-a79a00c7e55a --><h3>What adverse effects are associated with flucloxacillin?</h3><!-- end field a8c04b3c-a46e-4e8b-9707-a79a00c7e55a -->","summary":"","htmlStringContent":"<!-- begin item c9e2716b-8934-46b6-855e-a79a00c7e315 --><!-- begin field c08392ce-5cfb-4dda-9b35-a79a00c7e55a --><ul><li><strong>Diarrhoea</strong> is a common adverse effect of flucloxacillin.<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with flucloxacillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Cholestatic jaundice and hepatitis</strong> may occur (very rarely) up to several weeks after treatment with flucloxacillin has been stopped. Risk factors include treatment for more than 2 weeks and increasing age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">CSM, 1992</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">CSM, 2004</a>].</li><li><strong>Other rare (or uncommon) adverse effects include</strong> anaphylaxis, angioedema, urticaria, hypersensitivity reactions, rashes, joint pains, fever, and serum sickness-like reaction.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2016a</a>]</p><!-- end field c08392ce-5cfb-4dda-9b35-a79a00c7e55a --><!-- end item c9e2716b-8934-46b6-855e-a79a00c7e315 -->","subChapters":[]},{"id":"2c39c87d-a479-50dd-8761-cf35bc770523","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ec73fe8f-1702-4930-8050-a79a00c7f8a7 --><h3>What drug interactions are associated with flucloxacillin?</h3><!-- end field ec73fe8f-1702-4930-8050-a79a00c7f8a7 -->","summary":"","htmlStringContent":"<!-- begin item 11405468-b9ee-4dac-97d3-a79a00c7f6de --><!-- begin field 2bb4363e-b58f-4f1c-974d-a79a00c7f8a7 --><ul><li><strong>Possible drug interactions with flucloxacillin include:</strong><ul><li><strong>Anticoagulants (for example warfarin) </strong>— prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Consider monitoring the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Methotrexate </strong>— flucloxacillin may reduce clearance of methotrexate and increase the risk of toxicity. Consider monitoring concurrent use. </li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of flucloxacillin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>flucloxacillin</strong><strong>, </strong>see the <a data-hyperlink-id=\"0c9af016-e6fb-49ce-9f19-a99100442302\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"0daee820-e565-4d00-a220-a99100442327\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">FSRH, 2017</a>]</p><!-- end field 2bb4363e-b58f-4f1c-974d-a79a00c7f8a7 --><!-- end item 11405468-b9ee-4dac-97d3-a79a00c7f6de -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}